COVID-19 vaccine hesitancy in underserved communities of North Carolina. 2021

Irene A Doherty, and William Pilkington, and Laurin Brown, and Victoria Billings, and Undi Hoffler, and Lisa Paulin, and K Sean Kimbro, and Brittany Baker, and Tianduo Zhang, and Tracie Locklear, and Seronda Robinson, and Deepak Kumar
Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC, United States of America.

In the United States, underserved communities including Blacks and Latinx are disproportionately affected by COVID-19. This study sought to estimate the prevalence of COVID-19 vaccine hesitancy, describe attitudes related to vaccination, and identify correlates among historically marginalized populations across 9 counties in North Carolina. We conducted a cross-sectional survey distributed at free COVID-19 testing events in underserved rural and urban communities from August 27 -December 15, 2020. Vaccine hesitancy was defined as the response of "no" or "don't know/not sure" to whether the participant would get the COVID-19 vaccine as soon as it became available. The sample comprised 948 participants including 27.7% Whites, 59.6% Blacks, 12.7% Latinx, and 63% female. 32% earned <$20K annually, 60% owned a computer and ~80% had internet access at home. The prevalence of vaccine hesitancy was 68.9% including 62.7%, 74%, and 59.5% among Whites, Blacks, and Latinx, respectively. Between September and December, the largest decline in vaccine hesitancy occurred among Whites (27.5 percentage points), followed by Latinx (17.6) and only 12.0 points among Blacks. 51.2% of respondents reported vaccine safety concerns, 23.7% wanted others to get vaccinated first, and 63.1% would trust health care providers about the COVID-19 vaccine. Factors associated with hesitancy in multivariable logistic regression included being female (OR = 1.90 95%CI [1.36, 2.64]), being Black (OR = 1.68 1.16, 2.45]), calendar month (OR = 0.76 [0.63, 0.92]), safety concerns (OR = 4.28 [3.06, 5.97]), and government distrust (OR = 3.57 [2.26, 5.63]). This study engaged the community to directly reach underserved minority populations at highest risk of COVID-19 that permitted assessment of vaccine hesitancy (which was much higher than national estimates), driven in part by distrust, and safety concerns.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009657 North Carolina State bounded on the north by Virginia, on the east and Southeast by the Atlantic Ocean, on the south by Georgia and South Carolina, and on the west by Tennessee.
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086663 COVID-19 Vaccines Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19. 2019 Novel Coronavirus Vaccine,2019 Novel Coronavirus Vaccines,2019-nCoV Vaccine,2019-nCoV Vaccines,COVID 19 Vaccine,COVID-19 Vaccine,COVID-19 Virus Vaccine,COVID-19 Virus Vaccines,COVID19 Vaccine,COVID19 Vaccines,COVID19 Virus Vaccine,COVID19 Virus Vaccines,Coronavirus Disease 2019 Vaccine,Coronavirus Disease 2019 Vaccines,Coronavirus Disease 2019 Virus Vaccine,Coronavirus Disease 2019 Virus Vaccines,Coronavirus Disease-19 Vaccine,Coronavirus Disease-19 Vaccines,SARS Coronavirus 2 Vaccines,SARS-CoV-2 Vaccine,SARS-CoV-2 Vaccines,SARS2 Vaccine,SARS2 Vaccines,2019 nCoV Vaccine,2019 nCoV Vaccines,COVID 19 Vaccines,COVID 19 Virus Vaccine,COVID 19 Virus Vaccines,Coronavirus Disease 19 Vaccine,Coronavirus Disease 19 Vaccines,SARS CoV 2 Vaccine,SARS CoV 2 Vaccines,Vaccine, 2019-nCoV,Vaccine, COVID 19,Vaccine, COVID-19,Vaccine, COVID-19 Virus,Vaccine, COVID19,Vaccine, COVID19 Virus,Vaccine, Coronavirus Disease-19,Vaccine, SARS-CoV-2,Vaccine, SARS2,Vaccines, 2019-nCoV,Vaccines, COVID-19,Vaccines, COVID-19 Virus,Vaccines, COVID19,Vaccines, COVID19 Virus,Vaccines, Coronavirus Disease-19,Vaccines, SARS-CoV-2,Vaccines, SARS2,Virus Vaccine, COVID-19,Virus Vaccine, COVID19,Virus Vaccines, COVID-19,Virus Vaccines, COVID19
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Irene A Doherty, and William Pilkington, and Laurin Brown, and Victoria Billings, and Undi Hoffler, and Lisa Paulin, and K Sean Kimbro, and Brittany Baker, and Tianduo Zhang, and Tracie Locklear, and Seronda Robinson, and Deepak Kumar
September 2021, Delaware journal of public health,
Irene A Doherty, and William Pilkington, and Laurin Brown, and Victoria Billings, and Undi Hoffler, and Lisa Paulin, and K Sean Kimbro, and Brittany Baker, and Tianduo Zhang, and Tracie Locklear, and Seronda Robinson, and Deepak Kumar
January 2021, Texas medicine,
Irene A Doherty, and William Pilkington, and Laurin Brown, and Victoria Billings, and Undi Hoffler, and Lisa Paulin, and K Sean Kimbro, and Brittany Baker, and Tianduo Zhang, and Tracie Locklear, and Seronda Robinson, and Deepak Kumar
February 2022, Global health, science and practice,
Irene A Doherty, and William Pilkington, and Laurin Brown, and Victoria Billings, and Undi Hoffler, and Lisa Paulin, and K Sean Kimbro, and Brittany Baker, and Tianduo Zhang, and Tracie Locklear, and Seronda Robinson, and Deepak Kumar
July 2022, Nature reviews. Nephrology,
Irene A Doherty, and William Pilkington, and Laurin Brown, and Victoria Billings, and Undi Hoffler, and Lisa Paulin, and K Sean Kimbro, and Brittany Baker, and Tianduo Zhang, and Tracie Locklear, and Seronda Robinson, and Deepak Kumar
April 2023, Vaccines,
Irene A Doherty, and William Pilkington, and Laurin Brown, and Victoria Billings, and Undi Hoffler, and Lisa Paulin, and K Sean Kimbro, and Brittany Baker, and Tianduo Zhang, and Tracie Locklear, and Seronda Robinson, and Deepak Kumar
January 2022, Academic pediatrics,
Irene A Doherty, and William Pilkington, and Laurin Brown, and Victoria Billings, and Undi Hoffler, and Lisa Paulin, and K Sean Kimbro, and Brittany Baker, and Tianduo Zhang, and Tracie Locklear, and Seronda Robinson, and Deepak Kumar
January 2021, North Carolina medical journal,
Irene A Doherty, and William Pilkington, and Laurin Brown, and Victoria Billings, and Undi Hoffler, and Lisa Paulin, and K Sean Kimbro, and Brittany Baker, and Tianduo Zhang, and Tracie Locklear, and Seronda Robinson, and Deepak Kumar
June 2023, Journal of racial and ethnic health disparities,
Irene A Doherty, and William Pilkington, and Laurin Brown, and Victoria Billings, and Undi Hoffler, and Lisa Paulin, and K Sean Kimbro, and Brittany Baker, and Tianduo Zhang, and Tracie Locklear, and Seronda Robinson, and Deepak Kumar
April 2021, EClinicalMedicine,
Irene A Doherty, and William Pilkington, and Laurin Brown, and Victoria Billings, and Undi Hoffler, and Lisa Paulin, and K Sean Kimbro, and Brittany Baker, and Tianduo Zhang, and Tracie Locklear, and Seronda Robinson, and Deepak Kumar
February 2024, Journal of community health,
Copied contents to your clipboard!